The clinical gold standard for appetite regulation.
Semaglutide is a long-acting GLP-1 receptor agonist that mimics a gut hormone your body already produces. It slows gastric emptying, blunts hunger signaling in the hypothalamus, and improves glycemic control — producing meaningful, durable weight reduction when paired with physician oversight.
GLP-1 receptors in the arcuate nucleus modulate satiety signaling. Most patients report markedly quieter cravings and earlier fullness within the first two weeks.
Food remains in the stomach longer, extending satiety after meals and reducing post-meal glucose spikes.
Trials show reductions in HbA1c, fasting insulin, triglycerides, waist circumference and systolic blood pressure alongside weight loss.
The SELECT trial reported a 20% reduction in major adverse cardiovascular events in overweight adults with established cardiovascular disease.
Unlike thermogenic agents, semaglutide works on hormonal signaling — no jitteriness, no scheduled stimulant, no daily dosing.
Dosing is titrated by your physician against labs, side effects and body composition so results hold beyond the first plateau.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by intestinal L-cells after eating. Native GLP-1 degrades within minutes. Semaglutide is structurally modified to resist DPP-4 enzymatic breakdown and bind albumin, extending its half-life to roughly one week.
Semaglutide binds GLP-1 receptors in the pancreas, gut, and central nervous system with high affinity.
Pancreatic beta cells release insulin only when glucose is elevated, and glucagon secretion is suppressed — which is why hypoglycemia risk stays low in non-diabetics.
Gut motility slows, flattening the post-prandial glucose curve and extending mechanical satiety.
Signaling in the hypothalamus and hindbrain reduces homeostatic hunger and hedonic food reward, lowering overall caloric intake.
Obesity is regulated by a defended body-weight set point maintained by leptin, ghrelin and GLP-1 signaling. When you diet, ghrelin rises and energy expenditure falls — the body actively resists loss. GLP-1 agonists change the signal itself rather than asking the patient to out-discipline their own physiology.
Our compounded semaglutide is dispensed by U.S. PCAB-accredited 503A/503B pharmacies against a physician prescription. Active pharmaceutical ingredient is sourced from FDA-registered facilities with certificates of analysis available on request.
Roughly a quarter of weight lost on GLP-1 therapy can be lean tissue if unmanaged. Your protocol pairs adequate protein targets (1.6 g/kg), resistance training guidance, and optional peptide adjuncts to preserve muscle during the deficit.
Weight regain is common on abrupt discontinuation because the underlying signaling reverts. We plan maintenance dosing, tapers, and behavioral scaffolding from day one rather than at the end.
1,961 adults without diabetes; mean weight change of −14.9% with semaglutide 2.4 mg vs −2.4% placebo at 68 weeks.
New England Journal of Medicine
Continued treatment produced a further −7.9% loss, while switching to placebo produced +6.9% regain — evidence that the effect is pharmacologic, not habit-based.
JAMA
17,604 patients; 20% relative reduction in major adverse cardiovascular events independent of diabetes status.
New England Journal of Medicine
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly | Tolerance building. Not a therapeutic dose. |
| Weeks 5–8 | 0.5 mg weekly | First appetite effects typically consolidate. |
| Weeks 9–12 | 1.0 mg weekly | Escalate only if side effects are controlled. |
| Weeks 13–16 | 1.7 mg weekly | Physician reviews labs and rate of loss. |
| Week 17+ | 2.4 mg weekly | Maintenance target for most patients. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | ~15% | Weekly |
| Tirzepatide | GIP + GLP-1 agonist | ~21% | Weekly |
| Liraglutide | GLP-1 agonist | ~8% | Daily |
Appetite suppression usually appears within one to two weeks. Meaningful scale movement typically begins around week four and compounds as doses escalate through month three.
Subcutaneous injection into the abdomen, thigh, or back of the arm all work. The needle is 29–31 gauge and most patients describe it as painless.
Message your care team. We hold or reduce the dose rather than pushing through — titration speed is fully adjustable and most nausea resolves within days at a stable dose.
Moderate alcohol is not contraindicated, but it can worsen nausea and reflux and adds low-satiety calories. Many patients find their desire for it drops on its own.
Obesity is a chronic condition. Many patients transition to a lower maintenance dose or an extended interval. Your physician builds that plan with you rather than stopping abruptly.
Dual incretin action for the deepest documented weight reduction.
View protocolA gastric peptide studied for systemic tissue repair.
View protocolA synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolA mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolAn on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolThe original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.